Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · IEX Real-Time Price · USD
4.540
-0.070 (-1.52%)
At close: Jul 2, 2024, 4:00 PM
4.520
-0.020 (-0.44%)
After-hours: Jul 2, 2024, 6:49 PM EDT
Editas Medicine Revenue
Editas Medicine had revenue of $69.41M in the twelve months ending March 31, 2024, with 204.54% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.14M, a -88.48% decrease year-over-year. In the year 2023, Editas Medicine had annual revenue of $78.12M with 296.32% growth.
Revenue (ttm)
$69.41M
Revenue Growth
+204.54%
P/S Ratio
5.38
Revenue / Employee
$261,913
Employees
265
Market Cap
373.36M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
Dec 31, 2015 | 1.63M | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bioventus | 522.74M |
Health Catalyst | 296.79M |
Talkspace | 162.13M |
AC Immune | 16.82M |
Fate Therapeutics | 6.48M |
Precigen | 5.44M |
Fulcrum Therapeutics | 2.51M |
IGM Biosciences | 2.11M |
EDIT News
- 18 days ago - Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress - GlobeNewsWire
- 18 days ago - Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress - GlobeNewsWire
- 7 weeks ago - Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June - GlobeNewsWire
- 7 weeks ago - Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 7 weeks ago - Editas Medicine Announces First Quarter 2024 Results and Business Updates - GlobeNewsWire
- 2 months ago - Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events - GlobeNewsWire
- 2 months ago - Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration - GlobeNewsWire
- 2 months ago - Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire